Shares of Spark Therapeutics Inc. (NASDAQ:ONCE) have been given a consensus recommendation of “Hold” by the fourteen research firms that are covering the firm. Three research analysts have rated the stock with a sell recommendation, four have issued a hold recommendation and seven have assigned a buy recommendation to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $60.17.

Several research firms recently commented on ONCE. Zacks Investment Research upgraded Spark Therapeutics from a “hold” rating to a “buy” rating and set a $66.00 price objective on the stock in a research note on Thursday, August 11th. Cantor Fitzgerald reissued a “buy” rating and set a $94.00 target price on shares of Spark Therapeutics in a report on Thursday, August 11th. Stifel Nicolaus began coverage on shares of Spark Therapeutics in a report on Friday, September 2nd. They set a “buy” rating and a $73.00 target price on the stock. Chardan Capital reissued a “neutral” rating and set a $47.50 target price (down previously from $55.00) on shares of Spark Therapeutics in a report on Monday, November 7th. Finally, Wedbush reissued an “underperform” rating and set a $29.00 target price (up previously from $28.00) on shares of Spark Therapeutics in a report on Wednesday, August 10th.

In other Spark Therapeutics news, insider Barge Joseph La sold 3,000 shares of the company’s stock in a transaction dated Monday, October 3rd. The shares were sold at an average price of $60.14, for a total transaction of $180,420.00. Following the completion of the sale, the insider now directly owns 8,325 shares in the company, valued at $500,665.50. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Katherine A. High sold 10,000 shares of the company’s stock in a transaction dated Thursday, September 15th. The shares were sold at an average price of $60.37, for a total transaction of $603,700.00. Following the sale, the insider now owns 220,500 shares of the company’s stock, valued at $13,311,585. The disclosure for this sale can be found here. Company insiders own 9.60% of the company’s stock.

A number of hedge funds have recently bought and sold shares of ONCE. Price T Rowe Associates Inc. MD raised its stake in Spark Therapeutics by 9.3% in the third quarter. Price T Rowe Associates Inc. MD now owns 2,906,496 shares of the company’s stock valued at $174,564,000 after buying an additional 248,309 shares during the last quarter. Credit Suisse AG raised its stake in Spark Therapeutics by 15.3% in the third quarter. Credit Suisse AG now owns 25,656 shares of the company’s stock valued at $1,541,000 after buying an additional 3,397 shares during the last quarter. Endurant Capital Management LP acquired a new stake in Spark Therapeutics during the third quarter valued at about $348,000. Baker BROS. Advisors LP acquired a new stake in Spark Therapeutics during the third quarter valued at about $79,180,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in Spark Therapeutics during the third quarter valued at about $780,000. Institutional investors and hedge funds own 84.40% of the company’s stock.

Shares of Spark Therapeutics (NASDAQ:ONCE) traded down 1.89% during midday trading on Monday, hitting $55.47. The company’s stock had a trading volume of 183,774 shares. Spark Therapeutics has a 52-week low of $21.20 and a 52-week high of $65.99. The stock’s 50 day moving average is $53.56 and its 200-day moving average is $54.23. The firm’s market cap is $1.71 billion.

Spark Therapeutics (NASDAQ:ONCE) last announced its earnings results on Thursday, November 3rd. The company reported ($1.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.01) by $0.06. Spark Therapeutics had a negative return on equity of 28.28% and a negative net margin of 441.05%. The business earned $1.30 million during the quarter, compared to analysts’ expectations of $1.26 million. During the same quarter in the previous year, the firm earned ($0.70) EPS. Spark Therapeutics’s quarterly revenue was up .0% on a year-over-year basis. Equities analysts predict that Spark Therapeutics will post ($4.17) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Spark Therapeutics Inc. (ONCE) Given Consensus Rating of “Hold” by Analysts” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another site, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The original version of this news story can be read at https://www.thecerbatgem.com/2016/11/28/spark-therapeutics-inc-once-given-consensus-rating-of-hold-by-analysts.html.

Spark Therapeutics Company Profile

Spark Therapeutics, Inc (Spark) is engaged in developing products in the field of gene therapy. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its SPK-RPE65 (voretigene neparvovec) targets genetic blinding conditions known as inherited retinal dystrophies (IRDs).

5 Day Chart for NASDAQ:ONCE

Receive News & Stock Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related stocks with our FREE daily email newsletter.